Edition:
United States

Bristol-Myers Squibb Co (BMY.N)

BMY.N on New York Stock Exchange

61.32USD
17 Nov 2017
Change (% chg)

$-0.55 (-0.89%)
Prev Close
$61.87
Open
$61.56
Day's High
$61.89
Day's Low
$61.00
Volume
1,527,661
Avg. Vol
1,537,556
52-wk High
$66.09
52-wk Low
$46.01

Chart for

About

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small... (more)

Overall

Beta: 1.17
Market Cap(Mil.): $100,362.40
Shares Outstanding(Mil.): 1,636.70
Dividend: 0.39
Yield (%): 2.54

Financials

  Industry Sector
P/E (TTM): -- 31.35 15.79
EPS (TTM): -- -- --
ROI: -- 15.11 12.01
ROE: -- 16.52 15.91

Roche announces trial successes in cancer, haemophilia

ZURICH Roche announced a double dose of trial wins on Monday, saying its immunotherapy Tecentriq mixed with other drugs made advances against lung cancer, while data suggested its haemophilia agent Hemlibra could be used by more patients.

2:50am EST

UPDATE 2-Roche announces trial successes in cancer, haemophilia

* Roche playing catch-up in cancer immunotherapy (Adds detail about shares)

2:45am EST

BRIEF-Labcorp announces new expanded use for PD-L1 test with Bristol-Myers Squibb's Opdivo

Nov 15 Laboratory Corporation Of America Holdings

Nov 15 2017

BRIEF-Bristol-Myers and Syngene expand ongoing research collaboration

* Bristol-Myers Squibb and Syngene International expand ongoing research collaboration

Nov 14 2017

BRIEF-Syngene International ‍expands collaboration with Bristol-Myers Squibb​

* Nnext phase of partnership will see addition of facility to support future Bristol-Myers Squibb research and development operations​ Source text: http://bit.ly/2iT2tvz Further company coverage:

Nov 13 2017

BRIEF-Bristol-Myers says encouraging response observed with Opdivo plus BMS-986205, in heavily pre-treated patients with advanced cancers in early-stage study

* Encouraging response observed with Opdivo (nivolumab) plus investigational ido1 inhibitor, BMS-986205, in heavily pre-treated patients with advanced cancers in phase 1/2a study ca017-003

Nov 10 2017

BRIEF-Bristol-Myers and Five Prime present early-stage data evaluating Cabiralizumab with Opdivo in patients with advanced solid tumors

* Bristol-Myers Squibb and Five Prime present phase 1a/1b data evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in patients with advanced solid tumors

Nov 09 2017

BRIEF-Bristol-Myers Opdivo plus Yervoy combination delivered overall survival benefit across PD-l1 expression levels

* Opdivo plus Yervoy combination delivered overall survival benefit across PD-l1 expression levels in intermediate- and poor-risk patients with previously untreated advanced or metastatic renal cell carcinoma

Nov 07 2017

BRIEF-Calithera Biosciences expands clinical collaboration with Bristol-Myers Squibb

* Initial results from Phase 2 study of CB-839 in combination with opdivo® (nivolumab) to be presented at the Society for Immunotherapy of Cancer Meeting

Nov 07 2017

BRIEF-Opdivo demonstrates superior 3-yr survival benefit for patients with previously treated advanced RCC

* Opdivo (nivolumab) demonstrates superior three-year survival benefit for patients with previously treated advanced renal cell carcinoma (RCC)

Nov 06 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $138.00 -0.87
Pfizer Inc. (PFE.N) $35.37 -0.19
Merck & Co., Inc. (MRK.N) $55.20 +0.03
Sanofi SA (SASY.PA) €75.56 +0.13
AstraZeneca plc (AZN.L) 4,975.00 -36.00
GlaxoSmithKline plc (GSK.L) 1,311.00 +3.00
Eli Lilly and Co (LLY.N) $82.89 -0.55
Roche Holding Ltd. (ROG.S) CHF230.10 +1.10
Roche Holding Ltd. (RO.S) CHF241.10 +7.80

Earnings vs. Estimates